Updates are available Correction dated 2025-10-13

Article History

Received: 15 April 2025

Accepted: 29 June 2025

First Online: 30 July 2025

Change Date: 13 October 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00277-025-06632-3

Declarations

:

: AQ has declared consultancy fees with AstraZeneca, Janssen Cilag, Beigene, Lilly and Abbvie. SL has declared consultancy fees with AstraZeneca, Janssen Cilag, Abbvie, Beigene and Lilly. MSD has declared consultancy fees with Abbvie, Janssen-Cilag, AstraZeneca and Beigene. LB has has declared consultancy fees with Janssen Cilag, AstraZeneca, Beigene and Abbvie. RG has declared consultancy fees with Janssen Cilag, AstraZeneca, Beigene, Roche, Abbvie and Lilly. CD has declared board, consultation with Beigene, Janssen, Lilly, Abbvie, et AstraZeneca, local meeting with Beigene, Janssen; travel congress with: Beigene, Lilly, Janssen, Abbvie, AstraZeneca; travel grant and congress: Beigene, Lilly, Janssen, Abbvie, AstraZeneca. PF has declared consultancy fees with AstraZeneca, Janssen Cilag, Abbvie, Beigene and Lilly. DRW declared consultancy fees with AstraZeneca, Janssen Cilag, Abbvie, Beigene and Lilly. KL has grants from AstraZeneca and Abbvie, board of directors with Takeda, Novartis, Abbvie, Beigene, Pfizer, Jansen Cilag, honoraria with Jansen Cilag, BMS, GSK, Takeda, AbbVie, Amgen. LY has declared consultancy fees with Abbvie AstraZeneca Beigene BMS Gilead Janssen Cilag and Roche. VL has declared consultancy fees with Abbvie, AstraZeneca, BeiGene, Janssen-Cilag, Lilly. Other authors (ZM, OB, AS, GD) declared no COI.

: Patients were informed of the study and did not oppose to their data collection before being enrolled, with adapted measures regarding deceased patients in accordance with local regulations.